Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant mitotane versus observation after complete resection of low-intermediate risk adrenocortical carcinoma
NL-OMON36658Phase 3Active, not recruiting
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in adrenal cancer (ACC) comparing Mitotane with Observation only (2 arms). Primary endpoint: Recurrence-free survival. Started Oct 2011; status: active, not recruiting.
02
Drugs
mitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on NL-OMON36658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36658.